BiotechTube

ISB 1342

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsed/Refractory Multiple Myeloma

Conditions

Relapsed/Refractory Multiple Myeloma

Trial Timeline

Oct 25, 2017 → Dec 15, 2023

NCT ID
NCT03309111

About ISB 1342

ISB 1342 is a phase 1 stage product being developed by Glenmark Pharmaceuticals for Relapsed/Refractory Multiple Myeloma. The current trial status is completed. This product is registered under clinical trial identifier NCT03309111. Target conditions include Relapsed/Refractory Multiple Myeloma.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT03309111Phase 1Completed

Competing Products

20 competing products in Relapsed/Refractory Multiple Myeloma

See all competitors
ProductCompanyStageHype Score
agenT-797MiNK TherapeuticsPhase 1
25
Valemetostat TosylateDaiichi SankyoPhase 2
52
Eribulin mesylateEisaiPhase 2
52
Tirabrutinib + Rituximab + TemozolomideOno PharmaceuticalPhase 3
77
Epcoritamab + Epcoritamab + rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone + Venetoclax + Epcoritamab + Lenalidomide + Epcoritamab + Pirtobrutinib + EpcoritamabEli LillyPhase 1/2
41
SHR2554; Chidamide analog tablets + SHR2554 analog tablets; ChidamideJiangsu Hengrui MedicinePhase 3
77
Linperlisib ； RituximabJiangsu Hengrui MedicinePhase 1/2
41
Epcoritamab + Epcoritamab, lenalidomide and rituximabAbbViePhase 2
52
EtentamigAbbViePhase 1
33
Venetoclax + Bortezomib + Dexamethasone + Placebo for venetoclaxAbbViePhase 3
77
Etentamig + Dexamethasone + Lenalidomide + Pomalidomide + DaratumumabAbbViePhase 1
33
[14C]ABT-199 (GDC-0199)AbbViePhase 1
33
ABT-199 + bortezomib + dexamethasoneAbbViePhase 1
33
Venetoclax + DexamethasoneAbbViePhase 1/2
41
ABBV-453 + Dexamethasone + Daratumumab + LenalidomideAbbViePhase 1
33
mRNA-2752 + DurvalumabAstraZenecaPhase 1
33
AZD4573AstraZenecaPhase 2
52
Moxetumomab PasudotoxAstraZenecaPre-clinical
23
Administration of AZD6738AstraZenecaPhase 1
33
BlinatumomabAmgenPhase 2
51

Other Products from Glenmark Pharmaceuticals

Nitric OxidePhase 3
77
Fluticasone propionate Inhalation Aerosol 44 mcg + FLOVENT HFA 44 mcg + Matching Placebo inhalerPhase 3
77
Diclofenac Sodium gel, 1% + Voltaren® Gel + PlaceboPhase 3
77
Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064% + Enstilar® foam (LEO Pharma Inc.)Phase 3
77
Calcipotriene/Betamethasone Dipropionate + Taclonex® + PlaceboPhase 3
77